Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.53 |
| ▸ | GRN | P28799 | 8/20 | 0.52 |
| ▸ | SORT1 | Q99523 | 8/20 | 0.52 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CCKBR | P32239 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23213841 | 1.00 | GPR139 (0.53) | GPR139GRNSORT1KDM4CCA2 | |
| SCHEMBL31360685 | 0.89 | GRN (0.64) | GPR139GRNSORT1KDM4CCA2 | |
| SCHEMBL23213655 | 0.89 | GRN (0.64) | GPR139GRNSORT1KDM4CCA2 | |
| SCHEMBL23213654 | 0.89 | GRN (0.64) | GPR139GRNSORT1KDM4CCA2 | |
| SCHEMBL30714943 | 0.78 | GRN (0.49) | GRNSORT1KDM4CCA2CA1 | |
| SCHEMBL23212876 | 0.78 | GRN (0.49) | GRNSORT1KDM4CCA2CA1 | |
| SCHEMBL23212875 | 0.78 | GRN (0.49) | GRNSORT1KDM4CCA2CA1 | |
| SCHEMBL5747070 | 0.76 | HPGD (0.61) | GPR139KDM4CCA2CA1ALDH1A1 | |
| SCHEMBL2159492 | 0.76 | HPGD (0.61) | GPR139KDM4CCA2CA1ALDH1A1 | |
| SCHEMBL27611123 | 0.76 | ALDH1A1 (0.68) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4041393-B1 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | BAYER AG (DE) | 2026-04-08 | — | — | EP | disclosed |
| US-20230028441-A1 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | ELANCO ANIMAL HEALTH GMBH (DE) | 2023-01-26 | — | — | US | disclosed |
| EP-4041393-A1 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | Bayer Aktiengesellschaft (DE) | 2022-08-17 | — | — | EP | disclosed |
| WO-2021069567-A1 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028441-A1 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | PRXL2A, GLRX3, CYP4F3 | GPR139 2706/4885GRN 3383/4885SORT1 4774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.